A total of 43% of tumours (n = 22/51) were ER/PR+ HER2−, 22% (n = 11/51) were ER/PR+ HER2+, 12% (n = 6/51) were ER/PR− HER2+, and 24% (n = 12/51) triple-negative. This evidence concerns the gene ERBB2 and neoplasm.